Clinical trials: Essential Hypertension.
Essential Hypertension
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2…
- Trial name
- Benibest (NCT00890591)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Volunteers
- 144 people
- Sponsor
- Daiichi Sankyo
Hypertension
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.
- Trial name
- NCT00262236
- Testing
- Aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 693 people
- Sponsor
- Novartis
Hypertension
Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)
The purpose of this study is to evaluate antihypertensive (lowering blood pressure) effectiveness of three combinations of approved study drugs compared to both study drugs being given alone.
- Trial name
- NCT00092209
- Testing
- MK0954A, hydrochlorothiazide (+) losartan potassium
- Volunteers
- 840 people
- Sponsor
- Organon and Co
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Essential Hypertension
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
- Trial name
- OSCAR (NCT00139698)
- Testing
- olmesartan alone or in combination with hydrochlorothiazide
- Where
- 32 sites in Colombia, Ecuador and 8 more
- Volunteers
- 410 people
- Sponsor
- Pfizer
Hypertension
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
- Trial name
- NCT00219063
- Testing
- aliskiren
- Where
- United States
- Volunteers
- 844 people
- Sponsor
- Novartis
Essential Hypertension
Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts.
- Trial name
- NCT02062645
- Testing
- amlodipine/valsartan
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Hypertension
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension.
- Trial name
- NCT03872232
- Testing
- Ezetimibe/Rosuvastatin, Telmisartan
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Addpharma Inc.
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension
- Trial name
- NCT01785472
- Testing
- LCZ696, Olmesartan
- Where
- 50 sites in China, Hong Kong and 5 more
- Volunteers
- 1,438 people
- Sponsor
- Novartis Pharmaceuticals
Uncontrolled Hypertension
EuroNetrod HTN OFF-Med Study of Renal Denervation With NetrodTM Six-electrode Radiofrequency RDN System
This randomized controlled investigation aims to evaluate the efficacy and safety of the Netrod™ RDN system in patients with uncontrolled primary hypertension in the absence of antihypertensive medication, comparing the outcomes…
- Trial name
- EuroNetrod (NCT06722651)
- Testing
- Netrod™ six-electrode radiofrequency renal denervation system
- Where
- Switzerland
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Essential Hypertension, Chronic Stable Angina
Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg
The purpose of this study is to compare the pharmacokinetic characteristics and safety of dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects.
- Conditions
- Essential Hypertension, Chronic Stable Angina, Congestive Heart Failure
- Trial name
- NCT01819870
- Testing
- Dilatrend SR capsule 32mg, Dilatrend IR tablet 25mg
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
In-practice Evaluation of Atacand 16mg Antihypertensive Effect
The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses
- Trial name
- NCT00802542
- Where
- 4 sites in Latvia
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Hypertension, Left Ventricular Hypertrophy
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.
- Conditions
- Hypertension, Left Ventricular Hypertrophy, Overweight
- Trial name
- ALLAY (NCT00219141)
- Testing
- Aliskiren 150/300 mg, Losartan 50/100 mg
- Where
- 9 sites in United States, Argentina and 7 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Hypertension
A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure
To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension
- Trial name
- HCT3012-X-111 (NCT00662610)
- Testing
- naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
- Where
- 29 sites in United States
- Volunteers
- 120 people
- Sponsor
- NicOx
Hypertension
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with…
- Trial name
- NCT01151410
- Testing
- Aliskiren, Enalapril
- Where
- 36 sites in United States, Guatemala and 5 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Cardiovascular Diseases
Global Paradise System US Post Approval Study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood…
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- US GPS (NCT06297291)
- Testing
- Paradise Ultrasound Renal Denervation Treatment
- Where
- 46 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- ReCor Medical, Inc.
Hypertension, Hypertension, Resistant to Conventional Therapy
RADIANCE Continued Access Protocol
RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects…
- Conditions
- Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE CAP (NCT05017935)
- Testing
- Renal Denervation
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- ReCor Medical, Inc.
Hypertension
High Dose BAYA1040_Nifedipine: a Long Term Combination Study
This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) with other antihypertensives in patients with essential hypertension who are not at…
- Trial name
- NCT01294215
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 4 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Essential Hypertension
Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
The purpose of this study is to evaluate the long-term safety and tolerability of the combination of aliskiren and amlodipine given to patients with essential hypertension.
- Trial name
- NCT01237873
- Testing
- Ali/Amlo 150/2.5 mg
- Where
- 13 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Micardis®. Observational Study in Patients With Essential Hypertension
This study is designed to supplement, under conditions of usual clinical practice, the data on the efficacy and safety of Micardis® collected during the clinical studies.
- Trial name
- NCT02200094
- Testing
- Low dose of Telmisartan, once daily, High dose of Telmisartan, once daily
- Volunteers
- 4,532 people
- Sponsor
- Boehringer Ingelheim